Vaccines for bovine tuberculosis: Current views and future prospects

Expert Review of Vaccines

Volumn 4, Issue 6, 2005, Pages 891-903

  Hope, Jayne C ^a   Vordermeier, H Martin ^b  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

Bacillus Calmette Gu rin; Bovine tuberculosis; Immunodiagnosis; Vaccination

Indexed keywords

BCG VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; LIVE VACCINE;

BACTERIAL VIRULENCE; BCG VACCINATION; CATTLE DISEASE; CYTOKINE RELEASE; DRUG ANTIGENICITY; DRUG RESEARCH; GENOMICS; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MYCOBACTERIUM BOVIS; NEWBORN CARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINE PRODUCTION;

EID: 29944431807     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.6.891     Document Type: Review

References (100)

1. Cosivi O, Grange JM, Daborn CJ et al. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg. Infect. Dis. 4(1), 59-70 (1998).
2. Krebs JR. Bovine tuberculosis in cattle and badgers. In: Ministry of Agriculture, Fisheries and Food Publications. London, UK (1997). Provides a good overview of bovine tuberculosis in Great Britain, and the recommendations of the scientific review.
3. Cousins DV. Mycobacterium bovis infection and control in domestic livestock. Rev. Sci. Tech. 20(1), 71-85 (2001).
4. Sub-Committee, IVS Development of vaccines for Bovine Tuberculosis. In: Defra Publications, London, UK. (2003).
5. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nature Rev. Immunol. 1(1), 20-30 (2001).
6. Wedlock DN, Vesosky B, Skinner MA et al. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis. Infect. Immun. 68(10), 5809-5815 (2000).
7. Wedlock DN, Skinner MA, Parlane NA et al. Vaccination with DNA vaccines encoding MPB70 or MPB83 or a MPB70 DNA prime-protein boost does not protect cattle against bovine tuberculosis. Tuberculosis 83(6), 339-349 (2003).
8. Wedlock DN, Keen DL, McCarthy AR, Andersen P, Buddle BM. Effect of different adjuvants on the immune responses of cattle vaccinated with Mycobacterium tuberculosis culture filtrate proteins. Vet. Immunol. Immunopathol. 86(1-2), 79-88 (2002).
9. Fine PE. The BCG story: lessons from the past and implications for the future. Rev. Infect. Dis. 11(Suppl. 2), S353-S359 (1989).
10. Francis J. Bovine Tuberculosis. Staples Press, London, UK (1947).
11. Francis JA. A Study of Tuberculosis in Animals and Man. Cassell, London, UK (1958).
12. Hewinson RG, Vordermeier HM, Buddle BM. Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics. Tuberculosis 83, 119-130 (2003).
13. Skinner MA, Wedlock DN, Buddle BM. Vaccination of animals against Mycobacterium bovis. Rev. Sci. Tech. 20(1), 112-132 (2001).
14. Ellwood DC, Waddington FG. A second experiment to challenge the resistance to tuberculosis in BCG vaccinated cattle in Malawi. Br. Vet. J. 128(12), 619-626 (1972).
15. Brandt L, Feino Cunha J, Weinreich Olsen A et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immunol. 70(2), 672-678 (2002).
16. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346(8986), 1339-1345 (1995).
17. Stanford JL, Shield MJ, Rook GA. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tuberculosis 62(1), 55-62 (1981).
18. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am. Rev. Respir. Dis. 94(4), 553-568 (1966).
19. Edwards ML, Goodrich JM, Muller D et al. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guerin. J. Infect. Dis. 145(5), 733-741 (1982).
20. Orme IM, Roberts AR, Collins FM. Lack of evidence for a reduction in the efficacy of subcutaneous BCG vaccination in mice infected with nontuberculous mycobacteria. Tuberculosis 67(1), 41-46 (1986).
21. Orme IM, Collins FM. Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect. Immunol. 44(1), 28-32 (1984).
22. Hope JC, Thom ML, Villarreal-Ramos B et al. Exposure to Mycobacterium avium induces low-level protection from Mycobacterium bovis infection but compromises diagnosis of disease in cattle. Clin. Exp. Immunol. 141(3), 432-439 (2005).
23. Buddle BM, de Lisle GW, Pfeffer A, Aldwell FE. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. Vaccine 13(12), 1123-1130 (1995).
24. Buddle BM, Keen D, Thomson A et al. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Res. Vet. Sci. 59(1), 10-16 (1995).
25. Skinner M, Buddle BM, Wedlock N et al. A DNA prime-BCG boost vaccination strategy in cattle induces protection against bovine tuberculosis. Infect. Immunol. 71, 4901-4907 (2003). First demonstration in a relevant target species that heterologous prime-boost strategies can improve Bacillus Calmette-Guérin (BCG) efficacy.
26. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9(3), 115-118 (2001).
27. Ginsberg AM. What's new in tuberculosis vaccines? Bull. World Health Organ. 80(6), 483-488 (2002).
28. McMurray DN. Recent progress in the development and testing of vaccines against human tuberculosis. Int. J. Parasitol. 33(5-6), 547-554 (2003).
29. Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA. Prospects for a better vaccine against tuberculosis. Tuberculosis 83(1-3), 213-219 (2003).
30. Young DB. Ten years of research progress and what's to come. Tuberculosis 83(1-3), 77-81 (2003).
31. McAdam RA, Weisbrod TR, Martin J et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immunol. 63(3), 1004-1012 (1995).
32. Bange FC, Brown AM, Jacobs WR Jr. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect. Immun. 64(5), 1794-1799 (1996).
33. Pavelka MS Jr, Jacobs WR Jr. Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guérin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J. Bacteriol. 181(16), 4780-4789 (1999).
34. Chambers MA, Williams A, Gavier-Widen D et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea-pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immunol. 68(12), 7094-7099 (2000).
35. Hondalus MK, Bardarov S, Russell R et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68(5), 2888-2898 (2000).
36. Wedlock DN, Aldwell FE, Collins DM et al. Immune responses induced in cattle by virulent and attenuated Mycobacterium bovis strains: correlation of delayed-type hypersensitivity with ability of strains to grow in macrophages. Infect. Immun. 67(5), 2172-2177 (1999).
37. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 20(7-8), 1126-1133 (2002).
38. Taracha ELN, Gilbert SC, Musoke AJ, Bishop R, Hill AVS. Heterologous prime-boost immunization of cattle with Mycobacterium tuberculosis antigen 85A induces antigen-specific T-cell responses. Infect. Immun. 71(12), 6906-6914 (2003).
39. Vordermeier HM, Rhodes SG, Dean G et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112(3), 461-470 (2004).
40. Bosio CM, Orme IM. Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice. Infect. Immun. 66(10), 5048-5051 (1998).
41. Hogarth PJ, Logan KE, Vordermeier HM et al. Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c-a member of the ESAT-6 gene family. Vaccine 23(20), 2557-2564 (2005).
42. Chambers MA, Stagg D, Gavier-Widen D et al. A DNA vaccine encoding MPB83 from Mycobacterium bovis reduces M. bovis dissemination to the kidneys of mice and is expressed in primary cell cultures of the European badger (Meles meles). Res. Vet. Sci. 71(2), 119-126 (2001).
43. Chambers MA, Williams A, Hatch G et al. Vaccination of guinea-pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. Infect. Immun. 70(4), 2159-2165 (2002).
44. Maue AC, Waters WR, Palmer MV et al. CD80 and CD86, but not CD154, augment DNA vaccine-induced protection in experimental bovine tuberculosis. Vaccine 23(6), 769-79 (2004).
45. Wedlock DN, Skinner MA, de Lisle GW et al. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis. Vet. Immunol. Immunopathol. 106(1-2), 53-63 (2005).
46. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20, 709-760 (2002).
47. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev. Immunol. 4(4), 249-258 (2004).
48. Rankin R, Pontarollo R, Gomis S et al. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20(23-24), 3014-3022 (2002).
49. Pontarollo RA, Rankin R, Babiuk LA et al. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet. Immunol. Immunopathol. 84(1-2), 43-59 (2002).
50. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143 (2004).
51. Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206(Pt 21), 3771-3779 (2003).
52. + T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38 (1999).
53. + T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18(7-8), 623-632 (1999).
54. Hanke T, Blanchard TJ, Schneider J et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16(5), 439-445 (1998).
55. Pancholi P, Liu Q, Tricoche N et al. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J. Infect. Dis. 182(1), 18-27 (2000).
56. +-T-cell epitopes from antigen 85A. Infect. Immun. 70(3), 1623-1626 (2002).
57. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69(2), 681-686 (2001).
58. Goonetilleke NP, McShane H, Hannan CM et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602-1609 (2003).
59. Tanghe A, D'Souza S, Rosseels V et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69(5), 3041-3047 (2001).
60. Skinner MA, Ramsay AJ, Buchan GS et al. A DNA prime-live vaccine boost strategy in mice can augment IFN-γ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108(4), 548-555 (2003).
61. Vordermeier HM, Lowrie DB, Hewinson RG. Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting. Vet. Microbiol. 93(4), 349-359 (2003).
62. Skinner MA, Wedlock DN, de Lisle GW et al. The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins Hsp65, Hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect. Immunol. 73, 4441-4444 (2005).
63. Wedlock DN, Denis M, Skinner MA et al. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect. Immunol. 73(6), 3540-3546 (2005). Demonstrates that protein subunit vaccine/BCG heterologous prime-boost strategy improves BCG efficacy in cattle.
64. Horwitz MA, Harth GA. New vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea-pig model of pulmonary tuberculosis. Infect. Immunol. 71(4), 1672-1679 (2003).
65. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant Bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA. 97(25), 13853-13858 (2000).
66. Conradt P, Hess J, Kaufmann SH. Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin. Microbes. Infect. 1(10), 753-764 (1999).
67. Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172(12), 7618-7628 (2004).
68. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen, P Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea-pig model. Infect. Immunol. 72(10), 6148-6150 (2004).
69. Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea-pig aerosol infection model of tuberculosis. Tuberculosis 85(1-2), 29-38 (2005).
70. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10(11), 1240-1244 (2004). First novel human tuberculosis vaccine strategy to enter human clinical trials.
71. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173(10), 6357-6365 (2004).
72. Marchant A, Goetghebuer T, Ota MO et al. Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Calmette-Guérin vaccination. J. Immunol. 163(4), 2249-2255 (1999).
73. + T lymphocytes. Eur. J. Immunol. 31(5), 1531-1535 (2001).
74. Osburn BI. Ontogeny of immune response in cattle. In: The Ruminant Immune System in Health and Disease. Morrison WI (Ed.). Cambridge University Press, Cambridge, UK. 252-260 (1986).
75. Buddle BM, Wedlock DN, Parlane NA et al. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect. Immunol. 71(11), 6411-6419 (2003). Demonstrates that neonatal BCG vaccination of calves is highly effective.
76. Hope JC, Thom ML, Villarreal-Ramos B et al. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin. Exp. Immunol. 139(1), 48-56 (2005). Demonstrates that neonatal BCG vaccination of calves is highly effective.
77. Hope JC, Sopp P, Howard CJ. NK-like CD8(+) cells in immunologically naive neonatal calves that respond to dendritic cells infected with Mycobacterium bovis BCG. J. Leukoc. Biol. 71(2), 184-194 (2002).
78. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284(5419), 1520-1523 (1999).
79. Gordon SV, Brosch R, Billault A et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol. Microbiol. 32(3), 643-655 (1999).
80. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178(5), 1274-1282 (1996).
81. Pollock JM, Andersen P. Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle. Infect. Immunol. 65(7), 2587-2592 (1997).
82. Pollock JM, Andersen P. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J. Infect. Dis. 175(5), 1251-1254 (1997).
83. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel BA. Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 144, 3195-3203 (1998).
84. van Pinxteren LA, Ravn P, Agger EM, Pollock J, Andersen P Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab. Immunol. 7(2), 155-160 (2000).
85. Buddle BM, Parlane NA, Keen DL et al. Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle by using recombinant mycobacterial antigens. Clin. Diagn. Lab. Immunol. 6(1), 1-5 (1999).
86. Vordermeier HM, Whelan A, Cockle PJ et al. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin. Diagn. Lab. Immunol. 8(3), 571-578 (2001).
87. Vordermeier HM, Chambers MA, Cockle PJ et al. Correlation of ESAT-6-specific γ-interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70(6), 3026-3032 (2002). Defines immunologic correlates of disease useful as prognostic of vaccine efficacy.
88. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537-544 (1998).
89. Garnier T, Eiglmeier K, Camus JC et al. The complete genome sequence of Mycobacterium bovis. Proc. Natl Acad. Sci. USA 100(13), 7877-7882 (2003).
90. Li L, Bannantine JP, Zhang Q et al. The complete genome sequence of Mycobacterium avium subspecies paratuberculosis. Proc. Natl Acad. Sci. USA 102(35), 12344-12349 (2005).
91. Cockle PJ, Gordon SV, Lalvani A et al. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect. Immun. 70(12), 6996-7003 (2002).
92. Mustafa AS, Cockle PJ, Shaban F, Hewinson RG, Vordermeier HM. Immunogenicity of Mycobacterium tuberculosis RD1 region gene products in infected cattle. Clin. Exp. Immunol. 130(1), 37-42 (2002).
93. Vordermeier HM, Cockle PC, Whelan A et al. Development of diagnostic reagents to differentiate between Mycobacterium bovis BCG vaccination and M. bovis infection in cattle. Clin. Diagn. Lab. Immunol. 6(5), 675-682 (1999).
94. Buddle BM. Vaccination of cattle against Mycobacterium bovis. Tuberculosis 81(1-2), 125-132 (2001).
95. + T cells in bovine tuberculosis in vivo. Infect. Immunol. 71(8), 4297-4303 (2003).
96. Dietrich J, Aagaard C, Leah R et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT 6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174(10), 6332-6339 (2005).
97. Langermans JA, Doherty TM, Vervenne RA et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23(21), 2740-2750 (2005).
98. Lightbody KA, Skuce RA, Neill SD, Pollock JM. Mycobacterial antigen-specific antibody responses in bovine tuberculosis: an ELISA with potential to confirm disease status. Vet. Rec. 142(12), 295-300 (1998).
99. Lyashchenko K, Whelan AO, Greenwald R et al. Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. Infect. Immun. 72(5), 2462-2467 (2004).
100. Vordermeier HM, Cockle PJ, Whelan AO et al. Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal tuberculin skin test. Vaccine 19(9-10), 1246-1255 (2000).